Compare Nirsevimab to Palivizumab for RSV Prevention

You’ll hear buzz about nirsevimab-alip (Beyfortus) to prevent respiratory syncytial virus (RSV) in young children.

RSV is the most common cause of hospitalization in US infants...and typically circulates from October through March. Almost 8 in 10 kids under age 2 who get hospitalized for RSV are otherwise healthy.

Nirsevimab is a monoclonal antibody given IM in the hospital or clinic...similar to palivizumab (Synagis). But nirsevimab has a broader indication...palivizumab is only for certain high-risk kids.